about
Antibody-drug conjugates as novel anti-cancer chemotherapeuticsMarked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibitionHepatitis C virus reactivation in cancer patients in the era of targeted therapies.Preparation and Antitumor Activity of CS5931, A Novel Polypeptide from Sea Squirt Ciona SavignyiMethods for site-specific drug conjugation to antibodies.CD30-positive cutaneous lymphoma: report of four cases with an emphasis on clinicopathological correlationsManagement of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.Natural product and natural product derived drugs in clinical trials.Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations.Brentuximab vedotin for the treatment of Hodgkin's lymphoma.Production of anti-cancer immunotoxins in algae: ribosome inactivating proteins as fusion partners.Primary cutaneous anaplastic large cell lymphoma."Neurological complications of new chemotherapy agents".Advances in native high-performance liquid chromatography and intact mass spectrometry for the characterization of biopharmaceutical products.A retrospective examination of the US Food and Drug Administration's clinical pharmacology reviews of oncology biologics for potential use of therapeutic drug monitoring.CYP Suppression in Human Hepatocytes by Monomethyl Auristatin E, the Payload in Brentuximab Vedotin (Adcetris®), is Associated with Microtubule Disruption.CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis.Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.Monoclonal antibodies against cutaneous T-cell lymphomas.
P2860
Q26800175-4FBF06D3-0F07-417E-9CF7-6ABFE59FCC71Q28829301-7ACF575C-C7C2-4816-B9F1-2551E60BA0AAQ33735212-DBC7968E-16F9-49E6-AC4D-C07C44DB63A4Q36763814-AB0E198B-D4E2-4759-BAA6-789D8799D598Q37593707-92E155D4-0779-4298-9BD4-69281CC89467Q37644628-3DED80B9-C616-4B64-86D7-9E646AEF8F95Q38164572-07AB674E-0AF6-4981-9D7B-E56AEC43DA5AQ38247457-43EDA731-B764-490A-8C38-4119F0057B24Q38388962-A79D5893-17EF-497C-84CE-19202762318FQ38476250-F35210E1-8A9B-4A58-AFA2-2D5629B680C4Q39146031-5C947BBE-B0DF-4FFC-9ABA-EBBDFB768AD0Q39200210-B649FC7E-553F-4ECE-91E3-66E9BBB23E4CQ45069581-CE74018D-17B5-4460-9EA6-81D190029B1EQ47589015-9B82407B-3A83-464E-AB51-4EB8435EB31AQ49221285-4ED70551-811F-4F2E-88DA-98CF695C20D2Q49629406-3091E473-0C0C-4290-A684-C0174D6E8272Q50484927-E712EB8A-9F36-4BA3-B33A-8A6A7AB476C1Q51356061-5236DFB6-F441-4A7F-834C-56E84CC9827EQ51803389-B26AEEE6-5FE8-4FC3-8353-B2AD8DE35F42
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Brentuximab vedotin
@en
type
label
Brentuximab vedotin
@en
prefLabel
Brentuximab vedotin
@en
P2860
P356
P1476
Brentuximab vedotin
@en
P2093
Eugen Dhimolea
Niels W C J van de Donk
P2860
P304
P356
10.4161/MABS.20230
P577
2012-07-01T00:00:00Z